ViroGates appoints Mark Christian Hvidberg da Silva as its new CFO

Company announcement no. 9-2019                                                                                             

Birkerød, 14 August 2019

ViroGates A/S (Nasdaq First North Denmark: VIRO), who delivers blood test systems, primarily for acute care departments in hospitals, today announces that Mark Christian Hvidberg da Silva will be joining ViroGates as the Company’s new CFO. The former CFO, May Britt Dyvelkov will remain with ViroGates in a new position as Vice President of Accounting. Mark is 29 years old and joins ViroGates from a position as Manager in the management consulting company QVARTZ, where he was heading several client projects within corporate strategy, go-to-market strategy, commercial excellence etc. Mark has previously also worked for Novozymes in Denmark and Nova Founders Capital in Malaysia and the Philippines.

Mark holds an M.Sc. in Economics and Business Administration (International Business) from the Copenhagen Business School.



In ViroGates, Mark will lead a CFO function with focus on executing strategy, reporting and finance. He will also be managing ViroGates’ investor relations activities, and his experience will be utilized as the Company continues to expand its market presence.

Mark will join ViroGates no later than 1 October 2019 and will become part of the Company’s management team.

Mark Christian Hvidberg da Silva says: “I am very excited to join ViroGates and contribute to the commercialisation of suPARnostic®. I look forward to being part of a strong team that will deliver on our mission to improve the life of individuals and reduce healthcare costs while creating long-term value for our investors."

  

CEO Jakob Knudsen, says in a comment: ”I am very pleased that Mark is joining our team here at ViroGates. Mark has a unique blend of financial competencies, international commercial skills, and a great personality and drive. I look very much forward to working with Mark to realize the potential of our business.”

For further information contact:

CEO Jakob Knudsen

Tel. (+45) 2113 1336, Email:

ViroGates A/S - CVR-nr. 25734033 - Blokken 45, DK-340 Birkerød -

Certified Advisor

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, Email:

About ViroGates

ViroGates is an international Medtech company headquartered in Denmark. ViroGates develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular to make a clinical decision on hospitalization or discharge of emergency patients, which can lead to better clinical decisions, faster discharge and optimization of healthcare resources. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, cancer, etc. The ViroGates test suPARnostic® measures the suPAR (Soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream, and with the suPARnostic® Quick Triage test, hospital staff will get answers in just 20 minutes. The prognostic value of suPARnostic® is validated by more than 500 clinical trials and studies which included more than 300,000 blood samples.

Attachment